Type 2 diabetes is a leading cause of cardiovascular disease, blindness, renal failure and neurologic dysfunction in the United States. Current epidemiologic studies estimate that nearly 24 million Americans have type 2 diabetes and another 57 million have impaired glucose tolerance known as "pre-diabetes." On the whole, therapies for the treatment of type 2 diabetes receive widespread, restriction-free reimbursement on low formulary tiers because health plans understand the value of early and aggressive glycemic control. Nonetheless, patent expiry of several branded anti-diabetic therapies over the next three years, most-notably Takeda's Actos, will not only lead to in-class generic erosion, but will likely negatively impact reimbursement of all branded oral therapies and GLP-1 inhibitors.

Using tiering and restrictions data from Fingertip Formulary, as well as insight from 44 pharmacy directors, this report determines the key trends in reimbursement of type 2 diabetes treatments, drivers of these trends, and how stakeholders can capitalize on future shifts in coverage to steal share from the competition.

Related Reports

Formulary Advantages in Type 2 Diabetes:Rebates and discounts dictate the formulary position of branded therapies among some U.S. health plans.

According to the Centers for Disease Control and Prevention (CDC), an estimated 25.8 million people in the United States have diabetes. Diabetes is the leading cause of kidney failure, nontraumatic lo...

View Details

Formulary Advantages in Atrial Fibrillation: How Will MCO Size Affect the Design of Factor Xa Formularies?

In the coming years, atrial fibrillation (AF) patients will increasingly have more choice for anticoagulation therapy. Although Boehringer Ingelheim’s Pradaxa (dabigatran etexilate) and emerging facto...

View Details

Formulary Advantages in Asthma and COPD Therapies: Formulary Advantages in Asthma and COPD Therapies - Abstract

The market for asthma and chronic obstructive pulmonary disease (COPD) has grown notably in recent years because of increasing prevalence and diagnosis rates for both conditions as well as the greater...

View Details

Formulary Advantages in Psychiatric Drugs: Medicare plans readily employ cost-sharing measures and formulary restrictions to direct early use of generics and preferred brands for psychiatry.

According to the National Institute of Mental Health, each year tens of millions of Americans are affected by mental illness. Although significant strides have been made toward understanding the patho...

View Details